These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 7697732)
81. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. Airas L; Hellman J; Salmi M; Bono P; Puurunen T; Smith DJ; Jalkanen S J Exp Med; 1995 Nov; 182(5):1603-8. PubMed ID: 7595232 [TBL] [Abstract][Full Text] [Related]
82. CD73 is expressed on invading T lymphocytes in the inflamed peripheral nerve. Meyer Zu Hörste G; Reiners J; Lehmann HC; Airas L; Kieseier BC Muscle Nerve; 2009 Aug; 40(2):287-9. PubMed ID: 19609917 [TBL] [Abstract][Full Text] [Related]
83. CD73: a novel target for cancer immunotherapy. Zhang B Cancer Res; 2010 Aug; 70(16):6407-11. PubMed ID: 20682793 [TBL] [Abstract][Full Text] [Related]
84. 5'-nucleotidase--an overview of the last three years. Thompson LF Adv Exp Med Biol; 1991; 309B():145-50. PubMed ID: 1781358 [No Abstract] [Full Text] [Related]
85. Ecto-5'-nucleotidase activity is not required for T cell activation through CD73. Gutensohn W; Resta R; Misumi Y; Ikehara Y; Thompson LF Cell Immunol; 1995 Apr; 161(2):213-7. PubMed ID: 7697732 [TBL] [Abstract][Full Text] [Related]
86. CD73 (ecto-5'-nucleotidase) on blood mononuclear cells. Regulation of ecto-5'-nucleotidase activity and antigenic heterogeneity of CD73 on blood mononuclear cells from healthy donors and from patients with immunodeficiency. Christensen LD APMIS Suppl; 1997; 73():1-28. PubMed ID: 9393563 [No Abstract] [Full Text] [Related]